These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12197225)

  • 21. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.
    Pennucci MC; Ardizzoni A; Pronzato P; Fioretti M; Lanfranco C; Verna A; Giorgi G; Vigani A; Frola C; Rosso R
    Cancer; 1997 May; 79(10):1897-902. PubMed ID: 9149015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
    Gabizon A; Shmeeda H; Barenholz Y
    Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors.
    El-Rayes BF; Ibrahim D; Shields AF; LoRusso PM; Zalupski MM; Philip PA
    Invest New Drugs; 2005 Jan; 23(1):57-62. PubMed ID: 15528981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.
    Lotem M; Hubert A; Lyass O; Goldenhersh MA; Ingber A; Peretz T; Gabizon A
    Arch Dermatol; 2000 Dec; 136(12):1475-80. PubMed ID: 11115157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
    Rose PG
    Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome.
    Safra T; Groshen S; Jeffers S; Tsao-Wei DD; Zhou L; Muderspach L; Roman L; Morrow CP; Burnett A; Muggia FM
    Cancer; 2001 Jan; 91(1):90-100. PubMed ID: 11148564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas.
    Chidiac T; Budd GT; Pelley R; Sandstrom K; McLain D; Elson P; Crownover R; Marks K; Muschler G; Joyce M; Zehr R; Bukowski R
    Invest New Drugs; 2000 Aug; 18(3):253-9. PubMed ID: 10958594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.
    Ellerhorst JA; Bedikian A; Ring S; Buzaid AC; Eton O; Legha SS
    Oncol Rep; 1999; 6(5):1097-9. PubMed ID: 10425308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience.
    Perez AT; Domenech GH; Frankel C; Vogel CL
    Cancer Invest; 2002; 20 Suppl 2():22-9. PubMed ID: 12442346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.
    Trafalis DT; Alifieris C; Krikelis D; Tzogkas N; Stathopoulos GP; Athanassiou AE; Sitaras NM
    Int J Clin Pharmacol Ther; 2012 Jul; 50(7):490-9. PubMed ID: 22578202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
    Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma.
    Mintzer DM; Kelsen D; Frimmer D; Heelan R; Gralla R
    Cancer Treat Rep; 1985 Jun; 69(6):711-2. PubMed ID: 4040424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.
    Hillerdal G; Sorensen JB; Sundström S; Vikström A; Hjerpe A
    Clin Respir J; 2008 Apr; 2(2):80-5. PubMed ID: 20298311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
    Katsumata N; Fujiwara Y; Kamura T; Nakanishi T; Hatae M; Aoki D; Tanaka K; Tsuda H; Kamiura S; Takehara K; Sugiyama T; Kigawa J; Fujiwara K; Ochiai K; Ishida R; Inagaki M; Noda K
    Jpn J Clin Oncol; 2008 Nov; 38(11):777-85. PubMed ID: 18927230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
    Gabizon A; Martin F
    Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
    Chahinian AP; Antman K; Goutsou M; Corson JM; Suzuki Y; Modeas C; Herndon JE; Aisner J; Ellison RR; Leone L
    J Clin Oncol; 1993 Aug; 11(8):1559-65. PubMed ID: 8336195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study.
    Ardizzoni A; Rosso R; Salvati F; Fusco V; Cinquegrana A; De Palma M; Serrano J; Pennucci MC; Soresi E; Crippa M
    Cancer; 1991 Jun; 67(12):2984-7. PubMed ID: 2044044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.